[Oligoprogression]

Strahlenther Onkol. 2015 May;191(5):453-5. doi: 10.1007/s00066-015-0826-2.
[Article in German]
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Combined Modality Therapy
  • Disease Progression
  • Dose Fractionation, Radiation
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Erlotinib Hydrochloride
  • Fluorodeoxyglucose F18
  • Humans
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Neoplasm Staging
  • Positron-Emission Tomography
  • Prognosis
  • Prospective Studies
  • Quinazolines / therapeutic use*
  • Radiosurgery / methods*
  • Radiotherapy Dosage
  • Retreatment
  • Survival Rate
  • Treatment Failure

Substances

  • Quinazolines
  • Fluorodeoxyglucose F18
  • Erlotinib Hydrochloride